Cargando…

BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort

INTRODUCTION: In early 2020, the novel SARS-CoV-2 virus began to spread around the world and claim victims. Initially, in the Western world, COVID-19-related mortality was due to illness in long-term care facilities (LTCFs). To manage the COVID-19 crisis in LTCFs in Israel, the Ministry of Health es...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldin, Sivan, Adler, Limor, Azuri, Joseph, Mendel, Liran, Haviv, Shay, Maimon, Nimrod
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Clinical Section: Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059015/ https://www.ncbi.nlm.nih.gov/pubmed/35134810 http://dx.doi.org/10.1159/000521899

Ejemplares similares

National Weekly SARS-CoV-2 RT-PCR Screening of All Workers in Long-Term Care Facilities Associated with Decrease in Resident Mortality Rate
por: Abu-Fraiha, Yasmeen, et al.
Publicado: (2023)

A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine
por: Martora, Fabrizio, et al.
Publicado: (2022)

Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty(®))
por: Held, Jürgen, et al.
Publicado: (2021)

Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients
por: Anastasi, Emanuela, et al.
Publicado: (2022)

A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
por: Shimada, Yoshitaka, et al.
Publicado: (2022)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Effusive–constrictive pericarditis after the second dose of BNT162b2 vaccine (Comirnaty): a case report
por: Viani, Giacomo Maria, et al.
Publicado: (2022)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Post-Vaccinal Encephalitis with Early Relapse after BNT162b2 (COMIRNATY) COVID-19 Vaccine: A Case Report
por: Vences, Miguel A., et al.
Publicado: (2022)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
por: Gringeri, Michele, et al.
Publicado: (2021)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report
por: Kaimori, Ryo, et al.
Publicado: (2022)

Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds
por: Ribak, Yaarit, et al.
Publicado: (2023)

Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study
por: Adler, Limor, et al.
Publicado: (2022)

Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
por: Rastawicki, Waldemar, et al.
Publicado: (2023)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021)

AVP deficiency (central diabetes insipidus) following immunization with anti-COVID-19 BNT162b2 Comirnaty vaccine in adolescents: A case report
por: Partenope, Cristina, et al.
Publicado: (2023)

Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021
por: Muhsen, Khitam, et al.
Publicado: (2022)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever
por: Shechtman, Liran, et al.
Publicado: (2022)

Maternal perinatal depression and health services utilisation in the first 2 years of life: a cohort study
por: Adler, Limor, et al.
Publicado: (2021)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid(®)) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty(®))
por: Nakayama, Tetsuo, et al.
Publicado: (2023)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays
por: Padoan, Andrea, et al.
Publicado: (2021)

Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
por: Faro-Viana, João, et al.
Publicado: (2022)

Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty(Ⓡ)])
por: Ando, Masaru, et al.
Publicado: (2022)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction
por: Ameratunga, Rohan, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Khan, Muhammad, et al.
Publicado: (2022)

SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021
por: Patalon, Tal, et al.
Publicado: (2022)

Antibody response to BNT162b2 mRNA vaccine in healthcare workers and residents in a long‐term care facility
por: Kitagawa, Takao, et al.
Publicado: (2022)

Utilizing wearable sensors for continuous and highly-sensitive monitoring of reactions to the BNT162b2 mRNA COVID-19 vaccine
por: Gepner, Yftach, et al.
Publicado: (2022)

Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study
por: Ripabelli, Giancarlo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a22ihdbh56eo16hbmfvluopdbe